Selumetinib

Evidence Level: L3

Predicted Indications: 10

Selumetinib
1. Pharmacist Assessment Report
Selumetinib: From Neurofibromatosis to Peripheral Nerve Schwannoma

Pharmacist Assessment Report

Selumetinib: From Neurofibromatosis to Peripheral Nerve Schwannoma

One-Sentence Summary

Selumetinib is a MEK inhibitor originally used to treat neurofibromatosis. The TxGNN model predicts it may be effective for Peripheral Nerve Schwannoma, with 3 clinical trials and 6 publications currently supporting this direction. These are mostly early-stage, small, or indirect.

Quick Overview

Item	Content
Original Indication	Neurofibromatosis
Predicted New Indication	Peripheral nerve schwannoma (the report’s primary prediction, chosen as the best-supported of the top 10 predictions)
TxGNN Prediction Score	99.95% (the top-ranked prediction, familial generalized lentiginosis, scores 99.96%, but has no supporting evidence)
Evidence Level	L3
US Market Status	Cancelled only (both NDAs are listed as cancelled in the data compiled for this report)
Number of NDAs	2
Recommended Decision	Hold

Note on selection: The top-ranked prediction (familial generalized lentiginosis) has no trials or literature. Peripheral nerve schwannoma (rank 9) is the best-supported prediction, so it is the focus here. Rhabdoid tumor (rank 3) has only indirect evidence. The other seven predictions are model output only (L5).

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Selumetinib is known as a MEK1/2 inhibitor, which blocks the RAS/MAPK signaling pathway. It is established for neurofibromatosis type 1 plexiform neurofibromas, a closely related nerve sheath tumor.

Loss of NF1 or NF2 in Schwann cells drives RAS/MAPK and related signaling, which gives a mechanistic reason to try MEK inhibition in schwannomas (PMID 38216572). Neurofibromatosis and schwannoma are both nerve sheath tumor conditions with overlapping pathway biology.

Clinical support in NF2-related schwannoma is still thin. It consists of one small, terminated Phase 2 trial and a case report of partial response in an NF2-associated ependymoma. No completed randomized trial exists.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03095248	Phase 2	Terminated	10	Selumetinib in NF2-related tumors with hearing decline or tumor growth. Directly relevant, but underpowered and no results retrieved.
NCT07707947	Phase 2	Not yet recruiting	20	Single-arm study of a MEK1/2 inhibitor (selumetinib per the title) in NF2-related schwannomatosis, adults and children. No results yet.
NCT07713745	Phase 2	Not yet recruiting	200	PRIME-NF2 platform-basket trial across vestibular and non-vestibular schwannomas, meningiomas and ependymomas. Selumetinib’s inclusion is unconfirmed.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
37906356	2023	Review	Current Oncology Reports	Management of nervous system tumors in neurofibromatosis, noting the role of MEK inhibitors.
37046591	2023	Review/Expert recommendations	Cancers	EURACAN recommendations on peripheral and cranial nerve tumors. Evidence is low because of rarity.
38058737	2023	Case report	Mol Ther Methods Clin Dev	Partial response to selumetinib in a patient with an NF2-associated ependymoma.
38216572	2024	Preclinical	Nature Communications	Functional interactions between NF1 and NF2 in Schwann cell tumors, with treatment resistance mechanisms.
33835000	2020	Case report	Acta Dermatovenerol Croat	Plexiform neurofibroma without NF1. Background only.
40861330	2025	Case report	Surgical Case Reports	Surgical management of a giant mediastinal schwannoma in NF1. Background only.

US Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
NDA213756	KOSELUGO (AstraZeneca)	Capsule	Not available (status: cancelled)
NDA219943	KOSELUGO (AstraZeneca)	Granule	Not available (status: cancelled)

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (MEK inhibitor)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Drug Interactions: The interaction screening returned 84 interacting drugs. Examples from the list reviewed:

Major: aprepitant, dexamethasone, clarithromycin, cobicistat
Moderate: acetylsalicylic acid, cimetidine, clotrimazole, deferasirox, apixaban, dipyridamole, cilostazol, and several other antithrombotic or antiplatelet agents

The Major interactions include agents that affect drug metabolism (such as CYP3A inhibitors), so co-medications need careful review.

Please refer to the package insert for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic basis is strong and selumetinib is established in the related NF1 plexiform neurofibroma setting. However, direct evidence in schwannoma is limited to one small terminated Phase 2 trial (10 patients), a case report, and two trials that have not started recruiting. The US NDAs are listed as cancelled, and the package insert safety data could not be retrieved. Evidence level is L3 at best, and the other nine predictions are L5 or indirect.

To proceed, the following is needed:

Results or publication from the terminated NCT03095248 trial
Early data from NCT07707947 and confirmation of selumetinib’s role in PRIME-NF2
Mechanism of action data and FDA package insert warnings and contraindications
Clarification of the regulatory status of the cancelled NDAs
A review of the major drug interactions for the likely patient population
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.